Serum activities of dipeptidyl peptidase-4 and adenosine deaminase in polycystic ovary syndrome: association with obesity. (3rd August 2019)

• Record Type: Journal Article
• Authors: Kahraman, Seda; Eroglu Altinova, Alev; Elgun, Serenay; Yalcin, Mehmet Muhittin; Aktas Yilmaz, Banu; Ozkan, Cigdem; Akturk, Mujde; Balos Toruner, Fusun
• Is Part Of: Gynecological endocrinology. Volume 35:Number 8(2019)
• Page Start: 714
• Page End: 718
• Publication Date: 2019-08-03
• Subjects: Adenosine deaminase -- dipeptidyl peptidase-4 -- obesity -- inflammation -- polycystic ovary syndrome; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.1080/09513590.2019.1581165
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: Dipeptidyl peptidase-4 (DPP-4) plays a role in metabolic and inflammatory diseases. Increased adenosine deaminase (ADA) has been suggested to induce insulin resistance and inflammation. We measured serum DPP-4 and ADA activities. Serum ADA activity was significantly higher in PCOS group ( p = .006), whereas there was no difference in serum DPP-4 activity between the groups ( p > .05). When the study subjects were divided into four groups in terms of obesity; an increasing trend in serum ADA activity between the groups was observed and ADA activity was significantly higher in overweight and obese patients with PCOS than nonobese controls ( p = .016), there were no significant differences between the other groups ( p > .05). A positive correlation was found between ADA and BMI in the whole group ( p = .022). Multivariate regression analyses revealed that significant determinants were diastolic blood pressure, ADA, and the presence of PCOS for DPP-4 ( R 2 = 0.344, F = 9.079, p < .001); the presence of PCOS and DPP-4 for ADA ( R 2 = 0.123, F = 6.302, p = .003). We demonstrated increased serum ADA activity as well as its association with obesity in PCOS, while there was no change in serum DPP-4 activity in women with PCOS.